Articles from: The Lancet Infectious Diseases
Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone in gonorrhoea treatment. Yet, 5 mg/kg gentamicin (maximum 400 mg) is not non-inferior...
-
New from @TheLancetInfDis Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial by @henryjdevries and colleagues https://t.co/K2fw5ORNlm https://t.co/K2fw5ORNlm - view on twitter
Mashup Score:1
The Lancet Infectious DiseasesTreating pharyngeal gonorrhoea continues to remain a challenge - 3 hours
Mashup Score:1
In The Lancet Infectious Diseases, Henry J C de Vries and colleagues1 report exciting results from their New AntiBiotic treatment Options for uncomplicated GOnorrhea...
-
Linked Comment by @fabian_kong and @JHocking01 discusses the results and the need for further trials on pharyngeal infections to optimise treatment. https://t.co/fkoJ3tRcyq - view on twitter
Mashup Score:29
The Lancet Infectious DiseasesThe origin of SARS-CoV-2 variants of concern - 3 days
Mashup Score:29
A narrative propagated by the media of SARS-CoV-2 variants of concern arising in people living with HIV does not tell the whole story. Talha...
-
RT @TheLancetInfDis: New news feature: The origin of #SARSCoV2 variants of concern https://t.co/9x6KV1b0IG - view on twitter
More coverage:
#sarscov2
RV3-BB was well tolerated and immunogenic when co-administered with Expanded Programme on Immunisation vaccines in a neonatal or infant schedule. A lower titre (mid-titre)...
-
New research Article: Neonatal #rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study https://t.co/I7w7TOfqqf 🇲🇼 - view on twitter
More coverage:
#rotavirus
The BLOOMY scores showed good discrimination and predictive values and could support the development of protocols to manage bloodstream infections and also help to...
-
New research Article: Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalised adults with bloodstream infections: a multicentre, prospective, cohort study https://t.co/xOxakglEmW by @EveTacconelli & colleagues. - view on twitter
Mashup Score:3
The Lancet Infectious DiseasesIn-hospital mortality of patients with severe bloodstream infection: only the tip of the iceberg - 4 days
Mashup Score:3
Many studies on severe infections use in-hospital mortality, 14-day mortality, or 30-day mortality, as classic endpoints. However, in the era of high-performance intensive care,...
-
Plus linked Comment: In-hospital mortality of patients with severe bloodstream infection: only the tip of the iceberg https://t.co/RX0Yrrcgt6 - view on twitter
Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone in gonorrhoea treatment. Yet, 5 mg/kg gentamicin (maximum 400 mg) is not non-inferior...
-
New research Article: Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital #gonorrhoea (NABOGO): a randomised, non-inferiority trial https://t.co/O7CCUJ9k8K - view on twitter
More coverage:
#gonorrhoea
Mashup Score:2
The Lancet Infectious DiseasesTreating pharyngeal gonorrhoea continues to remain a challenge - 4 days
Mashup Score:2
In The Lancet Infectious Diseases, Henry J C de Vries and colleagues1 report exciting results from their New AntiBiotic treatment Options for uncomplicated GOnorrhea...
-
Plus linked Comment: Treating pharyngeal #gonorrhoea continues to remain a challenge https://t.co/PonhGihgdS - view on twitter
More coverage:
#gonorrhoea
We identified two strategies that could maximise efforts to prevent cervical cancer in LMICs given constraints on vaccine supplies and costs and that would...
-
Over 80% of #CervicalCancer cases occur in low- & middle-income countries (LMICs). In @TheLancetInfDis, a modelling study identifies optimal #HPV vaccination strategies to prevent cervical cancer in LMICs, given constraints on vaccine supplies & costs. https://t.co/8PfkQ8qJau - view on twitter
Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone in gonorrhoea treatment. Yet, 5 mg/kg gentamicin (maximum 400 mg) is not non-inferior...
Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea… https://t.co/Gjdm7hXDic 1000 mg ertapenem is non-inferior to 500 mg ceftriaxone in gonorrhoea Rx. 5 mg/kg gentamicin (maximum 400 mg) is not non-inferior to ceftriaxone. - view on twitter